Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee.

Targeted therapies, such as tyrosine kinase inhibitors, have been found to dramatically improve survival in patients with advanced-stage NSCLC.

靶向治疗，如酪氨酸激酶抑制剂，已被发现能显著改善晚期非小细胞肺癌（NSCLC）患者的生存期。

However, treatment options remain limited for patients with early or locally advanced stage (I-III) NSCLC harboring driver mutations, when the disease is not resectable, or the patient is unsuitable for surgery due to poor fitness or comorbidities.

然而，对于携带驱动基因突变的早期或局部晚期（I-III期）非小细胞肺癌患者，当疾病无法切除，或患者因体能状况不佳或合并症而不适合手术时，治疗选择仍然有限。

There is growing interest in combining targeted therapies with radiotherapy to optimize treatment outcomes for this patient group.

越来越多的研究兴趣集中在将靶向治疗与放射治疗相结合，以优化这一患者群体的治疗结果。

Notably, a progression-free survivalbenefit has recently been reported with the third-generation tyrosine kinase inhibitor osimertinib in patients with inoperable, EGFR-mutated, stage III NSCLC after chemoradiotherapy.

最近报道了在不可手术切除、EGFR突变、III期NSCLC患者中，第三代酪氨酸激酶抑制剂奥希替尼在接受放化疗后带来了无进展生存期的益处。

A narrative review of the literature was performed using PubMed, OVID (EMBASE), and ClinicalTrials.gov to identify studies evaluating the combination of targeted therapies and radiotherapy in inoperable stages I to III NSCLC.

使用PubMed、OVID（EMBASE）和ClinicalTrials.gov对文献进行了叙述性综述，以识别评估靶向治疗与放疗联合在I至III期不可手术切除NSCLC中的研究。

This review provides a comprehensive overview of the incidenceof actionable driver alterations and emerging clinical evidence on combining targeted therapies with thoracic radiotherapy in patients with inoperable stages I to III NSCLC.

本综述全面概述了可操作驱动改变的发生率以及在I至III期不可手术非小细胞肺癌患者中结合靶向治疗与胸部放疗的新兴临床证据。

The toxicity profile of combination treatments, optimal sequencing strategies, ongoing clinical trials, and future perspectives in this field are highlighted.

本综述强调了联合治疗的毒性特征、最佳序列策略、正在进行的临床试验以及该领域未来展望。

In summary, a clear biological rationale supports the synergistic effects of combining targeted therapies with radiotherapy in the neoadjuvant, concurrent, and adjuvant settings.

总之，明确的生物学理论支持在新辅助、同步和辅助治疗中联合靶向治疗与放疗的协同效应。

Advanced clinical trial methodologies may facilitate further research in this area, particularly for rare genetic alterations, to improve outcomes for these patients.

先进的临床试验方法可能会促进这一领域的进一步研究，特别是针对罕见的遗传改变，以改善这些患者的治疗结果。